The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

Explaining the decision to re-employ the current drug controller general of India, the health ministry has told the ...

Liability and injury: Changes to the existing liability protections for certain vaccine makers and modifications to the list ...

The US Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) of Lupin’s Sacubitril and ...

X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that its Marketing Authorization Application (MAA) for ...

Mifepristone has been under attack by abortion opponents, with several states seeking in federal court to restrict its use.

The discovery and development of drugs in pharmacological research – including the risk assessment of active substances in ...

During COVID-19, researchers found that low-dose buprenorphine initiation for fentanyl users was largely unsuccessful, with ...

An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower ...

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion centers.

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

The Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for elamipretide for the treatment of Barth syndrome, a rare genetic disorder.